Evommune is a clinical-stage biotechnology company headquartered in Palo Alto, California, focused on developing therapies for chronic inflammatory diseases. The company's pipeline centers on two primary candidates: EVO756, which targets chronic spontaneous urticaria and atopic dermatitis, and EVO301, designed for atopic dermatitis and ulcerative colitis. Both programs represent the company's efforts to address key pathogenic drivers in these disease areas.
As a pre-revenue clinical-stage entity, Evommune does not currently generate revenue from product sales. The company operates with a lean organizational structure of 45 full-time employees and was incorporated in Delaware in 2020. Based in the United States, the company's operations are concentrated in California, with its development programs advancing through the clinical trial process.
No 10-K filings found.